Is Neuphoria Therapeutics Inc (NEUP) overvalued? · rev $15.0M
Neuphoria Therapeutics Inc (NEUP) is a biotechnology company listed on NASDAQ.
This page asks whether Neuphoria Therapeutics Inc (NEUP) looks expensive on cached numbers — not a short thesis.
Latest reported NEUP revenue for 2025-03-31 was $15.0M. Net income was $11.3M. NEUP currently screens at market cap $23.6M.
NEUP currently screens at market cap $23.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NEUP 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NEUP stock page for the full model, not this heading.
Not investment advice.